Qiang Wang1,2, Hei Man Wu3, Weihua Yue4,5, Hao Yan4,5, Yamin Zhang1,2, Liwen Tan6, Wei Deng1,2, Qi Chen6, Guigang Yang7, Tianlan Lu4,5, Lifang Wang4,5, Fuquan Zhang8, Jianli Yang9,10, Keqing Li11, Luxian Lv12, Qingrong Tan13, Hongyan Zhang8, Xin Ma7, Fude Yang14, Lingjiang Li6, Chuanyue Wang7, Xiaohong Ma1,2, Liansheng Zhao1,2, Hongyan Ren1,2, Hao Yu15, Yingcheng Wang1,2, Xun Hu2,16, Dai Zhang4,5, Pak Sham3, Tao Li1,2. 1. Mental Health Center and Psychiatric Laboratory, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China. 2. West China Brain Research Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China. 3. State Key Laboratory of Brain and Cognitive Sciences, Centre for Genomic Sciences, and Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, China. 4. Peking University Sixth Hospital (Institute of Mental Health), Beijing, China. 5. National Clinical Research Center for Mental Disorders and Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China. 6. Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 7. Beijing Anding Hospital, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China. 8. Wuxi Mental Health Center, Nanjing Medical University, Wuxi, China. 9. Institute of Mental Health, Tianjin Anding Hospital, Tianjin, China. 10. Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China. 11. Hebei Mental Health Center, Baoding, Hebei, China. 12. Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China. 13. Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China. 14. Beijing HuiLongGuan Hospital, Beijing, China. 15. Department of Psychiatry, Jining Medical University, Jining, China. 16. Biobank, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Abstract
Importance: The underlying mechanism for individual differences in patient response to antipsychotic medication remains unknown. Objective: To discover genes and gene sets harboring rare variants associated with short-term antipsychotic medication efficacy. Design, Setting, and Participants: In this multicenter, open-label, randomized clinical trial conducted between July 6, 2010, and December 31, 2011, 3023 patients recruited in China of Chinese Han descent with schizophrenia with total Positive and Negative Syndrome Scale (PANSS) score ≥ 60 received a 6-week treatment ofantipsychotic medications randomly chosen from 5 atypical and 2 typical antipsychotic medications. Whole-exome sequencing (WES) was performed in 316 participants (grouped into those with the best response [n=156] and those who had no response [n=160] to the antipsychotic medication prescribed), according to the total PANSS score reduction rate after 6 weeks of treatment. Validation was performed using targeted sequencing in an independent sample of 1920 patients. Data analyses was performed between March 15, 2016, and March 1, 2017. Main Outcomes and Measures: Drug efficacy at week 6 was assessed according to the change in PANSS scores from baseline. Extremely good and extremely poor responders were selected for an initial WES association study, from which a subset of genes showing putative association was selected for independent replication with a targeted sequencing approach. Results: Of the 3023 patients (1549 [51.24%] female and 1474 [48.8%] male; mean [SD] age, 31.2 [7.9] years), 2336 (77.3%) were eligible for genetic analysis. After quality-control exclusions, 316 patients (10.5%) were included for WES and 1920 (63.5%) were included for replication. In the WES discovery stage, 2 gene sets (reduced NMDA [N-methyl-D-aspartate]-mediated synaptic currents and reduced AMPA [α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid]-mediated synaptic currents) were found to be enriched with rare damaging variants in the nonresponder group, suggesting the involvement of these gene sets in antipsychotic medication efficacy. Reduced NMDA-mediated synaptic currents gene set was further replicated in an independent sample using targeting sequencing. No statistically significant differences in antipsychotic drug response were found among the patients who received different antipsychotic drugs. Conclusions and Relevance: Genetic variation in glutamatergic or NMDA neurotransmission is implicated in short-term antipsychotic medication efficacy; WES may have utility in the study of rare genetic variation in pharmacogenetics. Trial Registration: Chinese Clinical Trials Registry Identifier: ChiCTR-TRC-10000934.
RCT Entities:
Importance: The underlying mechanism for individual differences in patient response to antipsychotic medication remains unknown. Objective: To discover genes and gene sets harboring rare variants associated with short-term antipsychotic medication efficacy. Design, Setting, and Participants: In this multicenter, open-label, randomized clinical trial conducted between July 6, 2010, and December 31, 2011, 3023 patients recruited in China of Chinese Han descent with schizophrenia with total Positive and Negative Syndrome Scale (PANSS) score ≥ 60 received a 6-week treatment of antipsychotic medications randomly chosen from 5 atypical and 2 typical antipsychotic medications. Whole-exome sequencing (WES) was performed in 316 participants (grouped into those with the best response [n=156] and those who had no response [n=160] to the antipsychotic medication prescribed), according to the total PANSS score reduction rate after 6 weeks of treatment. Validation was performed using targeted sequencing in an independent sample of 1920 patients. Data analyses was performed between March 15, 2016, and March 1, 2017. Main Outcomes and Measures: Drug efficacy at week 6 was assessed according to the change in PANSS scores from baseline. Extremely good and extremely poor responders were selected for an initial WES association study, from which a subset of genes showing putative association was selected for independent replication with a targeted sequencing approach. Results: Of the 3023 patients (1549 [51.24%] female and 1474 [48.8%] male; mean [SD] age, 31.2 [7.9] years), 2336 (77.3%) were eligible for genetic analysis. After quality-control exclusions, 316 patients (10.5%) were included for WES and 1920 (63.5%) were included for replication. In the WES discovery stage, 2 gene sets (reduced NMDA [N-methyl-D-aspartate]-mediated synaptic currents and reduced AMPA [α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid]-mediated synaptic currents) were found to be enriched with rare damaging variants in the nonresponder group, suggesting the involvement of these gene sets in antipsychotic medication efficacy. Reduced NMDA-mediated synaptic currents gene set was further replicated in an independent sample using targeting sequencing. No statistically significant differences in antipsychotic drug response were found among the patients who received different antipsychotic drugs. Conclusions and Relevance: Genetic variation in glutamatergic or NMDA neurotransmission is implicated in short-term antipsychotic medication efficacy; WES may have utility in the study of rare genetic variation in pharmacogenetics. Trial Registration: Chinese Clinical Trials Registry Identifier: ChiCTR-TRC-10000934.
Authors: Seunggeun Lee; Mary J Emond; Michael J Bamshad; Kathleen C Barnes; Mark J Rieder; Deborah A Nickerson; David C Christiani; Mark M Wurfel; Xihong Lin Journal: Am J Hum Genet Date: 2012-08-02 Impact factor: 11.025
Authors: Shaun M Purcell; Jennifer L Moran; Menachem Fromer; Douglas Ruderfer; Nadia Solovieff; Panos Roussos; Colm O'Dushlaine; Kimberly Chambert; Sarah E Bergen; Anna Kähler; Laramie Duncan; Eli Stahl; Giulio Genovese; Esperanza Fernández; Mark O Collins; Noboru H Komiyama; Jyoti S Choudhary; Patrik K E Magnusson; Eric Banks; Khalid Shakir; Kiran Garimella; Tim Fennell; Mark DePristo; Seth G N Grant; Stephen J Haggarty; Stacey Gabriel; Edward M Scolnick; Eric S Lander; Christina M Hultman; Patrick F Sullivan; Steven A McCarroll; Pamela Sklar Journal: Nature Date: 2014-01-22 Impact factor: 49.962
Authors: Menachem Fromer; Andrew J Pocklington; David H Kavanagh; Hywel J Williams; Sarah Dwyer; Padhraig Gormley; Lyudmila Georgieva; Elliott Rees; Priit Palta; Douglas M Ruderfer; Noa Carrera; Isla Humphreys; Jessica S Johnson; Panos Roussos; Douglas D Barker; Eric Banks; Vihra Milanova; Seth G Grant; Eilis Hannon; Samuel A Rose; Kimberly Chambert; Milind Mahajan; Edward M Scolnick; Jennifer L Moran; George Kirov; Aarno Palotie; Steven A McCarroll; Peter Holmans; Pamela Sklar; Michael J Owen; Shaun M Purcell; Michael C O'Donovan Journal: Nature Date: 2014-01-22 Impact factor: 49.962
Authors: Giulio Genovese; Menachem Fromer; Eli A Stahl; Douglas M Ruderfer; Kimberly Chambert; Mikael Landén; Jennifer L Moran; Shaun M Purcell; Pamela Sklar; Patrick F Sullivan; Christina M Hultman; Steven A McCarroll Journal: Nat Neurosci Date: 2016-10-03 Impact factor: 24.884
Authors: H Hu; S A Haas; J Chelly; H Van Esch; M Raynaud; A P M de Brouwer; S Weinert; G Froyen; S G M Frints; F Laumonnier; T Zemojtel; M I Love; H Richard; A-K Emde; M Bienek; C Jensen; M Hambrock; U Fischer; C Langnick; M Feldkamp; W Wissink-Lindhout; N Lebrun; L Castelnau; J Rucci; R Montjean; O Dorseuil; P Billuart; T Stuhlmann; M Shaw; M A Corbett; A Gardner; S Willis-Owen; C Tan; K L Friend; S Belet; K E P van Roozendaal; M Jimenez-Pocquet; M-P Moizard; N Ronce; R Sun; S O'Keeffe; R Chenna; A van Bömmel; J Göke; A Hackett; M Field; L Christie; J Boyle; E Haan; J Nelson; G Turner; G Baynam; G Gillessen-Kaesbach; U Müller; D Steinberger; B Budny; M Badura-Stronka; A Latos-Bieleńska; L B Ousager; P Wieacker; G Rodríguez Criado; M-L Bondeson; G Annerén; A Dufke; M Cohen; L Van Maldergem; C Vincent-Delorme; B Echenne; B Simon-Bouy; T Kleefstra; M Willemsen; J-P Fryns; K Devriendt; R Ullmann; M Vingron; K Wrogemann; T F Wienker; A Tzschach; H van Bokhoven; J Gecz; T J Jentsch; W Chen; H-H Ropers; V M Kalscheuer Journal: Mol Psychiatry Date: 2015-02-03 Impact factor: 15.992
Authors: Sven Bölte; Kristiina Tammimies; Danyang Li; Nora Choque-Olsson; Hong Jiao; Nina Norgren; Ulf Jonsson Journal: NPJ Genom Med Date: 2020-10-12 Impact factor: 8.617